Single-dose protection, Valneva’s IXCHIQ chikungunya vaccine reaches US and EU markets

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 1:00 PM ET. Details in the imprint.

Valneva’s chikungunya vaccine IXCHIQ has quietly turned into a flagship asset for the French-Austrian biotech, as the single-dose shot rolls out in the US and secures wider approvals in Europe for adults at risk of the mosquito-borne disease. The product is currently the first and only chikungunya vaccine licensed in the United States for individuals 18 years and older who are at increased risk of exposure, including travelers heading to endemic regions. Valneva announced the initial US FDA approval in November 2023.

How IXCHIQ works and where the chikungunya shot is available

IXCHIQ (live, attenuated chikungunya vaccine) is designed as a one-dose intramuscular injection that uses a weakened form of the chikungunya virus to trigger a strong neutralizing antibody response, aiming to reduce the risk of symptomatic infection in adults living in or traveling to areas with ongoing transmission. In pivotal Phase 3 clinical data, a single injection produced seroprotective levels of neutralizing antibodies in the vast majority of participants and maintained high titers over at least six months, leading regulators to greenlight the product for those at increased risk of exposure. Peer-reviewed trial results in the New England Journal of Medicine reported robust seroresponse rates above 98 percent 28 days after vaccination.

The US Food and Drug Administration authorized IXCHIQ for adults 18 years and older who are at increased risk of chikungunya, such as travelers, researchers, military personnel and people with long-term stays in endemic regions in Africa, Asia and the Americas, and the shot is now being distributed primarily through travel medicine centers, specialized vaccination clinics and certain hospital-based providers. In April 2024 the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization under the name IXCHIQ for the same adult age group, and the European Commission has since granted approval, opening the door for national rollouts in EU and European Economic Area countries. According to a contemporaneous report from Reuters, this made Valneva’s product the first chikungunya vaccine to receive an EMA green light.

For Valneva, IXCHIQ sits alongside travel vaccines such as its inactivated Japanese encephalitis product Ixiaro and its cholera vaccine Dukoral as part of a focused portfolio targeting both endemic populations and high-risk travelers. Management has repeatedly highlighted chikungunya as a key growth driver given that the viral disease has caused millions of cases over the past two decades and is spreading into new regions as climate patterns and mosquito habitats shift, creating a market that spans Latin America, the Caribbean, South Asia and rising concern in parts of Europe and the southern United States. Shares of Valneva SE (FR0013280286) traded on Euronext Paris at around EUR 3.50 on 06/14/2026.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.